Hans-Peter Goertz, MPH
Articles
June 14th 2019
Understanding Price Growth in the Market for Targeted Oncology Therapies
Jesse Sussell, PhD Jacqueline Vanderpuye-Orgle, PhD Diana Vania, MSc Hans-Peter Goertz, MPH Darius Lakdawalla, PhD
The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.
Latest Updated Articles
Published: August 18th 2025 | Updated: August 25th 2025
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults
Published: August 19th 2025 | Updated: August 22nd 2025
Semaglutide Not Associated With Increased Risk of Eye Disorders
Published: June 6th 2025 | Updated: August 18th 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
